Epitalon is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, the molecular formula C₁₄H₂₂N₄O₉, and a molecular weight of 390.4 g/mol. It was developed at the Saint Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson as a defined-sequence analog of epithalamin, a peptide preparation extracted from bovine pineal gland. Ever Vital lists epitalon as a lyophilized research compound. It is studied in cell culture and animal models for its reported effects on telomerase expression, pineal function, and circadian regulation.
What is the difference between epitalon and epithalamin?
Epithalamin is a crude polypeptide extract of pineal tissue; epitalon is a single synthetic molecule. The Khavinson group's early work through the 1980s used epithalamin, an undefined mixture of pineal peptides, in animal and observational studies. Epitalon was designed afterward as a short sequence intended to reproduce the extract's activity in a chemically defined form suitable for controlled research. The two names are frequently used interchangeably in secondary sources, but the distinction matters when reading the literature: results reported for epithalamin were obtained with a mixture, and results reported for epitalon with the tetrapeptide.
What is the proposed telomerase mechanism?
The proposed mechanism is that epitalon induces expression of the catalytic subunit of telomerase (TERT) in cells that do not normally express it, with a resulting increase in telomerase activity and telomere length in those cells. The primary evidence comes from a 2003 report by the Khavinson group in human fetal fibroblast cultures, which described telomerase activity and telomere elongation in treated cells that were absent in controls, together with an extended replicative capacity. Later work from the same group described epitalon binding to DNA in the promoter region of genes including TERT in cell-free and cell models, proposing that the tetrapeptide acts as a direct transcriptional modulator. These are the findings behind every claim about epitalon and telomeres. They come from a small number of studies and, for the most part, a single research group.
In which cell models was telomerase activation reported?
Telomerase activation was reported principally in cultured human somatic fibroblasts, which normally lack telomerase and undergo replicative senescence. The finding of interest was that treated cultures passed the Hayflick limit observed in controls. Related work examined gene expression changes in retinal pigment epithelial cells and in pineal cell cultures. Independent replication in other laboratories, using different cell lines and modern telomerase assays, is limited, and that is the principal gap in the evidence.
What did the long-term studies report?
The Khavinson group reported observational studies in older adults followed for periods of six to twelve years, in which groups receiving epithalamin or epitalon were compared with untreated groups on mortality and on markers including melatonin and cortisol rhythms. Those reports described lower mortality and better-preserved circadian melatonin patterns in the treated groups. Separate animal studies in mice and rats reported increased mean lifespan and reduced spontaneous tumor incidence in treated cohorts.
What are the limitations of those studies?
The limitations are substantial and consistent across the body of work: small sample sizes, non-randomized or unclearly randomized allocation, absence of blinding, single-center design, and near-exclusive origin from one research group. The human observational reports lack the placebo control and pre-registration that would allow the mortality findings to be interpreted causally. The animal lifespan studies have not been reproduced in the large multi-site programs, such as the NIA Interventions Testing Program, that have evaluated other longevity candidates. Epitalon therefore occupies an unusual position: a consistent and mechanistically specific set of claims, with an evidence base that has not been independently tested at scale.
How is epitalon studied in the context of circadian and melatonin regulation?
Epitalon is studied for its effects on the pineal gland's nocturnal melatonin output. The Khavinson group reported that older primates and rats treated with the peptide showed restoration of the night-time melatonin peak that declines with age, and human observational data described a similar pattern. The proposed link between this and the telomerase findings is indirect: pineal function, circadian rhythm integrity, and cellular aging are treated as a connected system in the bioregulator literature, with epitalon positioned as acting on the pineal component. Researchers using it in circadian models typically measure melatonin and its metabolites, clock gene expression, and cortisol rhythms.
What is a bioregulator peptide and where does epitalon fit?
Bioregulator peptides, in the Khavinson framework, are short peptides (two to four residues) derived from or modeled on tissue extracts, proposed to regulate gene expression in the tissue of origin. Epitalon is the pineal representative. Others in the same family include thymalin (thymus) and pinealon (a tripeptide also modeled on pineal peptides), both of which Ever Vital lists alongside epitalon. The shared hypothesis is that these short sequences interact with DNA or chromatin in a sequence-specific way. That hypothesis is not established outside the originating literature, and it is the reason bioregulators are considered a distinct and contested category in longevity peptide research.
How does epitalon compare structurally to other short peptides in the catalog?
At four residues and 390 Da, epitalon is among the smallest peptides in the research catalog. It carries two acidic residues (glutamate and aspartate) flanked by alanine and glycine, giving it a net negative charge at physiological pH and high water solubility. It has no cysteine, no aromatic residues, and no cyclic constraint, so it lacks the features (disulfide bridges, hydrophobic cores) that stabilize longer signaling peptides. Its short, acidic profile is consistent with the proposed DNA-interacting mechanism and inconsistent with a classical receptor-ligand model. For analytical purposes it presents as a small polar peptide with weak UV absorbance at 280 nm (no tryptophan or tyrosine), so purity is assessed at 214 nm.
What is known about epitalon's stability and storage as a research compound?
As a short linear tetrapeptide without oxidizable residues, lyophilized epitalon is stable under standard conditions: stored at minus 20 degrees Celsius, protected from light and moisture, for the period stated on the lot's Certificate of Analysis. In solution it is susceptible to the aspartate-glycine sequence's known tendency toward isoaspartate formation over time, which is a consideration for any study running extended incubations. Purity by reverse-phase HPLC and identity by mass spectrometry (observed protonated mass near 391 Da) are the standard release tests.
Has epitalon been studied in any registered clinical trial?
No registered, controlled clinical trial of epitalon appears in the major trial registries as of publication. The human data consist of the observational reports described above. This is an important distinction from compounds such as the GLP-1 class or tesamorelin, where controlled trial data exist, and it is the main reason epitalon should be described as a research compound with a hypothesis rather than a compound with an established effect.
What should researchers take from the epitalon literature?
The epitalon literature offers a specific, testable hypothesis (transcriptional induction of TERT by a tetrapeptide) with preliminary in vitro support and a long tail of observational claims from a single group. That profile makes it a candidate for replication work rather than a settled mechanism. Researchers designing epitalon studies benefit from including telomerase activity assays with appropriate positive controls, more than one cell line, and blinded scoring, since those are the elements the existing evidence lacks.
All compounds referenced in this article are supplied for research purposes only and are not for human use. Nothing here describes or endorses any use of these materials outside laboratory research. These products are not intended to diagnose, treat, cure, or prevent any disease.
Join the list.
Restock alerts, subscriber discounts, and first access to new compound drops.
